An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · West Pharmaceutical Services, Inc.
VERDICT
The label
Markup
read at $337.00
West Pharmaceutical Services holds its Markup at $337.00.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-29
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 22 days
Price
$337.00
Valuation
42.39 trailing · 33.91 forward price to earnings
Values screen
PASS· score 85.8
Beta
1.16
OPPORTUNITY
The opportunity · what the numbers say it is worth
Our framework reads OVERVALUED — it trades above our $314.32 fair value estimate, moderate competitive moat, 13.80% revenue growth.
Read at
$337.00
42.39 P/E · 33.91 fwd
Our fair value
$314.32
7% premium
Analyst target (avg)
$410.00
+22% to current
Target low $340.00Analyst target rangeTarget high $459.00
▲ current $337.00 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$337.00
you are here
Conservative
$306.00
-9%
Analyst avg
$410.00
+22%
Our fair value
$314.32
-7%
Analyst high
$459.00
+36%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish — a quality-at-a-fair-price name rather than a deep-value one.
Revenue growth
13.80%
Profit margin
16.98%
Debt to equity
10.59
Analyst consensus
Strong Buy · 15 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 7.5% of its assets, well under the one-third ceiling — it does not run on borrowed money.Pass
Interest-bearing cashCash held in interest-bearing accounts and securities is 5.0% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 32.0% of assets, under the 49% limit.Pass
Revenue purityOnly 0.6% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
The quiet supplier behind every safe injection
Every time a biologic reaches a patient, it travels inside packaging that must not fail. West Pharmaceutical Services builds those vials and delivery systems across the Americas, Europe and Asia, posting 21% revenue growth, 17% profit margins and 19% ROE.
Those results are respectable, yet the shares sit 16% above our fair value at a 37 times forward earnings multiple. The market is already paying for strong growth that may not repeat at the same pace, leaving the stock overvalued on plain numbers.
A moderate moat and clean ethical screen reduce some concerns, but high valuation still leaves investors exposed if drug spending slows or input costs rise. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
WST trades on a US exchange. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 46%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it buy, with a mean price target of $350. Entered 2026-07-18 · Accumulation
JOURNAL
The dated journal · newest first, never edited
2026-07-18Accumulation$314.50+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 46%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it buy, with a mean price target of $350.
2026-07-03Accumulation$314.50+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Accumulation$314.50Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
